The American College of Physicians (ACP) recently issued a set of guidelines for glycated hemoglobin (A1c) treatment targets in patients with type 2 diabetes. These guidelines generated immediate controversy. An endocrinologist reviews the new guidelines and explains exactly why she disagrees with several of their key points: setting most A1c targets between 7% and 8%, scaling back treatment when A1c drops below 6.5%, and avoiding A1c targets altogether in elderly and chronically ill patients. Read more